Atnaujinkite slapukų nuostatas

El. knyga: Reactive Oxygen Species: Network Pharmacology and Therapeutic Applications

Edited by , Edited by , Edited by
Kitos knygos pagal šią temą:
Reactive Oxygen Species: Network Pharmacology and Therapeutic ApplicationsDidesnis paveikslėlis
Kitos knygos pagal šią temą:

DRM apribojimai

  • Kopijuoti:

    neleidžiama

  • Spausdinti:

    neleidžiama

  • El. knygos naudojimas:

    Skaitmeninių teisių valdymas (DRM)
    Leidykla pateikė šią knygą šifruota forma, o tai reiškia, kad norint ją atrakinti ir perskaityti reikia įdiegti nemokamą programinę įrangą. Norint skaityti šią el. knygą, turite susikurti Adobe ID . Daugiau informacijos  čia. El. knygą galima atsisiųsti į 6 įrenginius (vienas vartotojas su tuo pačiu Adobe ID).

    Reikalinga programinė įranga
    Norint skaityti šią el. knygą mobiliajame įrenginyje (telefone ar planšetiniame kompiuteryje), turite įdiegti šią nemokamą programėlę: PocketBook Reader (iOS / Android)

    Norint skaityti šią el. knygą asmeniniame arba „Mac“ kompiuteryje, Jums reikalinga  Adobe Digital Editions “ (tai nemokama programa, specialiai sukurta el. knygoms. Tai nėra tas pats, kas „Adobe Reader“, kurią tikriausiai jau turite savo kompiuteryje.)

    Negalite skaityti šios el. knygos naudodami „Amazon Kindle“.

Reactive oxygen species (ROS) have been implicated in almost every human disease phenotype, without much, if any, therapeutic consequence foremost exemplified by the failure of the so-called anti-oxidants. This book is a game changer for the field and many clinical areas such as cardiology and neurology. The term ‘oxidative stress’ is abandoned and replaced with a systems medicine and network pharmacology-based mechanistic approach to disease. The ROS-related drugs discussed here target either ROS- forming or ROS -modifying enzymes for which there is strong clinical evidence. In addition, ROS targets are included as they jointly participate in causal mechanisms of disease. This approach is transforming the ROS field and represents a breakthrough in redox medicine indicating a path to patient benefit. In the coming years more targets and drugs may be discovered, but the approach will remain the same and this book will thus become, and for many years remain, the leading reference for ROSopathies and their treatment by network pharmacology.  

Chapter "Soluble Guanylate Cyclase Stimulators and Activators" is available open access under a Creative Commons Attribution 4.0 International License via link.springer.com.  


Part I: ROS Revisited: Changing the Focus from Oxidative Stress and
Redox Biology to Redox Medicine.- Demystifying oxidative stress.- Oxidants in
Physiological Processes.- Network Medicine-Based Unbiased Disease Modules for
Drug and Diagnostic Target Identification in ROSopathies.- Part II Targeting
antioxidant responses.- Development of Telintra as an Inhibitor of
Glutathione S-Transferase P.- Perspectives on the Clinical Development of
NRF2-Targeting Drugs.- Part III: Inhibiting ROS formation and toxification.-
NOX Inhibitors: From Bench to Naxibs to Bedside.- Nitric Oxide Synthase
Inhibitors into the Clinic at Last.- Xanthine Oxidoreductase Inhibitors.-
Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches.-
Inhibition of Myeloperoxidase.- Part IV: Stimulating/substituting ROS.-
Effects of Mammalian Thioredoxin Reductase Inhibitors.- Cardiovascular
Therapeutic Potential of the Redox Siblings, Nitric Oxide (NO) and Nitroxyl
(HNO), in the Setting of Reactive Oxygen Species Dysregulation.-
Tetrahydrobiopterin and Nitric Oxide Synthase Recouplers.- Part V: Repairing
ROS damage.- Soluble Guanylate Cyclase Stimulators and Activators Peter
Sander.- Inhibitors of Advanced Glycation End Product (AGE) Formation and
Accumulation.
Daugiau apie elektronines knygas Daugiau apie elektronines knygas
Pastovi nuoroda: https://www.kriso.lt/db/97830306851022e.html
Raktažodžiai: